KR20040075096A - 유형i 당뇨를 치료하기 위한 약제 제조용 멜라가트란의용도 - Google Patents

유형i 당뇨를 치료하기 위한 약제 제조용 멜라가트란의용도 Download PDF

Info

Publication number
KR20040075096A
KR20040075096A KR10-2004-7011228A KR20047011228A KR20040075096A KR 20040075096 A KR20040075096 A KR 20040075096A KR 20047011228 A KR20047011228 A KR 20047011228A KR 20040075096 A KR20040075096 A KR 20040075096A
Authority
KR
South Korea
Prior art keywords
melagatran
pharmaceutically acceptable
acceptable derivative
kit
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR10-2004-7011228A
Other languages
English (en)
Korean (ko)
Inventor
올레 코르스그렌
보 닐슨
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20040075096A publication Critical patent/KR20040075096A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR10-2004-7011228A 2002-01-23 2003-01-21 유형i 당뇨를 치료하기 위한 약제 제조용 멜라가트란의용도 Withdrawn KR20040075096A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0200198-0 2002-01-23
SE0200198A SE0200198D0 (sv) 2002-01-23 2002-01-23 New use
PCT/SE2003/000087 WO2003061682A1 (en) 2002-01-23 2003-01-21 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus

Publications (1)

Publication Number Publication Date
KR20040075096A true KR20040075096A (ko) 2004-08-26

Family

ID=20286751

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7011228A Withdrawn KR20040075096A (ko) 2002-01-23 2003-01-21 유형i 당뇨를 치료하기 위한 약제 제조용 멜라가트란의용도

Country Status (14)

Country Link
US (2) US7045502B2 (cg-RX-API-DMAC7.html)
EP (1) EP1469874A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005516035A (cg-RX-API-DMAC7.html)
KR (1) KR20040075096A (cg-RX-API-DMAC7.html)
CN (1) CN100430089C (cg-RX-API-DMAC7.html)
BR (1) BR0306798A (cg-RX-API-DMAC7.html)
CA (1) CA2472241A1 (cg-RX-API-DMAC7.html)
IL (1) IL162853A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04007192A (cg-RX-API-DMAC7.html)
NO (1) NO20043483L (cg-RX-API-DMAC7.html)
NZ (1) NZ533749A (cg-RX-API-DMAC7.html)
SE (1) SE0200198D0 (cg-RX-API-DMAC7.html)
WO (1) WO2003061682A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200405342B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
WO2014149139A2 (en) 2013-03-15 2014-09-25 Verseon, Inc. Halogenopyrazoles as inhibitors of thrombin
DK2968297T3 (en) 2013-03-15 2019-01-07 Verseon Inc MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS
JP2017528486A (ja) 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
ES2931460T3 (es) 2015-02-27 2022-12-29 Verseon Int Corporation Compuestos de pirazol sustituido como inhibidores de serina proteasa
IL280078B2 (en) 2018-07-13 2024-04-01 Verseon Int Corporation Thrombin inhibitors, formulations, and uses thereof
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
CN121843705A (zh) 2023-05-03 2026-04-10 萨那生物科技公司 工程化胰岛细胞的给药和施用方法
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
WO2025043172A1 (en) 2023-08-23 2025-02-27 Sana Biotechnology, Inc. Modified cd47 proteins and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
AR005245A1 (es) 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9900070D0 (sv) * 1999-01-13 1999-01-13 Astra Ab New use
SE523817C2 (sv) 1999-02-05 2004-05-18 Corline Systems Ab Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use

Also Published As

Publication number Publication date
CN1729010A (zh) 2006-02-01
US20060148720A1 (en) 2006-07-06
NO20043483L (no) 2004-08-20
US20050090424A1 (en) 2005-04-28
BR0306798A (pt) 2004-12-07
CA2472241A1 (en) 2003-07-31
JP2005516035A (ja) 2005-06-02
MXPA04007192A (es) 2004-10-29
WO2003061682A1 (en) 2003-07-31
EP1469874A1 (en) 2004-10-27
SE0200198D0 (sv) 2002-01-23
US7045502B2 (en) 2006-05-16
CN100430089C (zh) 2008-11-05
IL162853A0 (en) 2005-11-20
ZA200405342B (en) 2005-09-28
NZ533749A (en) 2006-02-24

Similar Documents

Publication Publication Date Title
Ozmen et al. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation
JP2001513576A (ja) 側副経路を介する補体活性化を阻害するためのプロセス
US7045502B2 (en) Use of melagatran for the manufacture of a medicament for the treatment of Type 1 diabetes mellitus
CN109640959A (zh) 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
JP4315908B2 (ja) デキストラン硫酸エステルの新規用途
JP2007504167A (ja) 抗組織因子抗体を用いる移植片の生存を向上する方法
Waegell et al. A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection
US8048411B2 (en) Co-transplantation of hepatic stellate cells and islet cells
RU2315621C2 (ru) Применение ингибитора или антагониста тканевого фактора
JP2003501346A (ja) 移植手術における新規な使用
CN114762725B (zh) 一种治疗糖尿病的方法
CN114762697B (zh) 用于治疗糖尿病的药物及方法
AU2003202192A1 (en) The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus
WO2018137701A1 (zh) 靶向cxcr7的药物组合物和方法
Yoshimatsu et al. The impact of allogenic blood transfusion on the outcomes of total pancreatectomy with islet autotransplantation
RU2758536C1 (ru) Способ снижения воспалительной гиперактивации нейтрофилов
Yang et al. Blocking the CC chemokine receptor 5 pathway by antisense peptide nucleic acid prolongs islet allograft survival
WO2022143905A1 (zh) 一种治疗糖尿病的药物及其方法
Mattke Targeting Toll-Like Receptor 4 Related Inflammation Using Small Molecule, TAK-242, to Attenuate Inflammatory Damage in Pancreatitis and Islet Transplantation
Mineo et al. Islet and pancreas transplantation
Lee Islet surface PEGylation attenuate the instant blood-mediated inflammatory reaction in intrahepatic islet transplantation
Knochenmark et al. 18th Meeting of the Austrian Society of Transplantation, Transfusion and Genetics
Morton Evaluation of bioenergetic changes in acute pancreatitis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040720

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid